HbO

Hemoglobin Oxygen Therapeutics LLC

News

October 18, 2017
Hemoglobin Oxygen Therapeutics LLC Announces the World’s First Human Liver Transplantation After Ex-Situ Normothermic Machine Perfusion Using Hemopure

SOUDERTON, Pa., Oct. 18, 2017 /PRNewswire/ —┬áHemoglobin Oxygen Therapeutics LLC (HBO2 Therapeutics) is the leading developer of hemoglobin based solutions that increase the oxygen carrying capacity of blood. The Company announced today the 1st human organ transplant of a previously rejected liver, reconditioned ex-situ with a warm perfusion solution oxygenated with Hemopure prior to transplantation….

October 10, 2017
UMCG makes rejected donor liver suitable for transplantation

For the first time in the Netherlands, a patient has received a donor liver that was optimized in a perfusion machine after having been rejected for transplantation. The patient is making an excellent recovery. The transplant was part of an experiment in which donor livers considered unsuitable for transplantation are ‘refurbished’ in a perfusion machine….